CheckMate 214 at 9-Year Follow-Up
This Medudy course is a video tutorial for physicians on the topic “CheckMate 214: 9-Year Follow-Up.” Professor Günter Niegisch, Head of the Department of Conservative Urological Oncology at the University Hospital Düsseldorf, presents the long-term data from the CheckMate 214 study. The study compared the dual immunotherapy combination of nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) with the previous standard of care, sunitinib. The presentation focuses […]